Compare
COMPASS Pathways plc vs Puma Biotechnology, Inc. vs Abeona Therapeutics Inc. vs UroGen Pharma Ltd.
| Latest fiscal year | COMPASS Pathways plc CMPS | Puma Biotechnology, Inc. PBYI | Abeona Therapeutics Inc. ABEORevenue covers only part of its income (partial revenue) | UroGen Pharma Ltd. URGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $228.37M | n/a | $109.79M |
| Revenue growth (YoY) | n/a | -0.9% | n/a | +21.4% |
| Gross margin | n/a | 74.5% (computed) | n/a | 88.7% |
| Operating margin | n/a | 16.3% | n/a | -113.7% |
| Net margin | n/a | 13.6% | n/a | -139.8% |
| Net income | -$287.86M | $31.11M | $71.18M | -$153.49M |
| EPS (Diluted) | -$3.08 | $0.61 | $1.01 | n/a |
| Operating cash flow | -$157.24M | $41.80M | -$76.33M | -$162.44M |
| Free cash flow | n/a | $41.73M | -$84.30M | -$162.73M |
| Cash & equivalents | $149.61M | $29.64M | $78.44M | $110.75M |
| Total assets | $210.35M | $216.30M | $219.57M | $200.46M |
| Total liabilities | $263.20M | $85.96M | $60.35M | $305.93M |
| Shareholders' equity | -$52.85M | $130.34M | $159.22M | -$105.47M |
| Return on year-end equity | n/a | 23.9% | 44.7% | n/a |
| Shares outstanding | 96.09M | 50.41M | 55.04M | 48.35M |
Revenue, most recent five fiscal years
| Fiscal year | COMPASS Pathways plc | Puma Biotechnology, Inc. | Abeona Therapeutics Inc. | UroGen Pharma Ltd. |
|---|---|---|---|---|
| Latest | n/a | $228.37M Ended 2025-12-31 | n/a | $109.79M Ended 2025-12-31 |
| 1 year earlier | n/a | $230.47M Ended 2024-12-31 | n/a | $90.40M Ended 2024-12-31 |
| 2 years earlier | n/a | $235.64M Ended 2023-12-31 | n/a | $82.71M Ended 2023-12-31 |
| 3 years earlier | n/a | $228.03M Ended 2022-12-31 | n/a | $64.36M Ended 2022-12-31 |
| 4 years earlier | n/a | $253.16M Ended 2021-12-31 | n/a | $48.04M Ended 2021-12-31 |